^
    Back
    Association details:
    Biomarker:EGFR exon 19 deletion
    Cancer:Non Small Cell Lung Cancer
    Drug:BBT-176 (EGFR inhibitor, Tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment

    Excerpt:
    ...- Radiological documentation of disease progression while on a previous continuous (at least 30 days) treatment with an EGFR TKI monotherapy (including, but...
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2022
    Title:

    MA07.09 - BBT-176, a 4th generation EGFR TKI, for Progressed NSCLC after EGFR TKI Therapy: PK, Safety and Efficacy from Phase 1 Study

    Published date:
    07/12/2022
    Excerpt:
    Reduction in EGFR mutation allelic frequency was observed in three patients, including non-classical exon 19 deletion and T790M. These changes were correlated with tumor shrinkage in two of the patients. Two patients harboring triple mutations of exon 19 del/T790M/C797S showed radiological improvements in both target and non-target lesions. Continuous daily dosing of BBT-176 was well-tolerated with manageable toxicities.
    Trial ID:
    NCT04820023